SEK 1.17
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating type 2 diabetes. PILA PHARMA AB (publ) was founded in 2014 and maintains its headquarters in Malmö, Sweden.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only